(Q37253034)

19 August 2017

1 reference

title

Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects (English)

1 reference

19 August 2017

0 references

Agnes L F Chan

1

1 reference

19 August 2017

Yie W Chien

series ordinal

2

1 reference

19 August 2017

Shun Jin Lin

series ordinal

3

1 reference

19 August 2017

language of work or name

1 reference

1 January 2008

1 reference

19 August 2017

1 reference

19 August 2017

25

1 reference

19 August 2017

9

1 reference

19 August 2017

761-775

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200825090-00003

19 August 2017

0 references

cites work

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825090-00003

Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825090-00003

Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825090-00003

The importance of neuritic plaques and tangles to the development and evolution of AD

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825090-00003

Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825090-00003

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825090-00003

Estrogen Receptor 1 gene (ESR1) variants in Alzheimer's disease. Results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200825090-00003

Hormone replacement therapy for cognitive function in postmenopausal women.

21 January 2018

1 reference

12 December 2020

Amyloid precursor protein and presenilin involvement in cell signaling.

1 reference

12 December 2020

An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003

1 reference

12 December 2020

Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life

1 reference

12 December 2020

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease

1 reference

12 December 2020

Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial

1 reference

12 December 2020

Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

1 reference

12 December 2020

Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment

1 reference

12 December 2020

The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism

1 reference

12 December 2020

Mitochondrial cascade hypothesis of Alzheimer's disease: myth or reality?

1 reference

12 December 2020

Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease

1 reference

12 December 2020

Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease

1 reference

12 December 2020

Alzheimer Disease in the US Population

1 reference

12 December 2020

Neuronal cell cycle re-entry mediates Alzheimer disease-type changes

1 reference

12 December 2020

Hormone replacement therapy to maintain cognitive function in women with dementia.

1 reference

12 December 2020

Should titration schedules for cholinesterase inhibitors be changed?

1 reference

12 December 2020

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

1 reference

12 December 2020

Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease

1 reference

12 December 2020

Transdermal patches are more than skin deep.

1 reference

12 December 2020

Development and in vivo assessment of a transdermal system for physostigmine

1 reference

12 December 2020

Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery

1 reference

12 December 2020

Mitochondrial Aβ A potential cause of metabolic dysfunction in Alzheimer's disease

1 reference

12 December 2020

Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease

1 reference

12 December 2020

Diagnostics and therapy of Alzheimer's disease.

1 reference

12 December 2020

Synaptic targeting by Alzheimer's-related amyloid beta oligomers.

1 reference

12 December 2020

Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety.

1 reference

12 December 2020

Changes in brain cholinesterases in senile dementia of Alzheimer type.

1 reference

12 December 2020

Treatment of Alzheimer's disease: current status and new perspectives.

1 reference

12 December 2020

Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats

1 reference

12 December 2020

Transgenic mice over-expressing human beta-amyloid have functional nicotinic alpha 7 receptors.

1 reference

12 December 2020

Inhibition of human cholinesterases by drugs used to treat Alzheimer disease

1 reference

12 December 2020

Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides

1 reference

12 December 2020

Nicotine-induced enhancement of synaptic plasticity at CA3-CA1 synapses requires GABAergic interneurons in adult anti-NGF mice.

1 reference

12 December 2020

Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.

1 reference

12 December 2020

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

1 reference

12 December 2020

Neuropathologic changes in Alzheimer's disease

1 reference

12 December 2020

Alzheimer therapeutics-what after the cholinesterase inhibitors?

1 reference

12 December 2020

Cholinesterase inhibitors for Alzheimer's disease

1 reference

12 December 2020

Controlled transdermal iontophoresis by ion-exchange fiber.

1 reference

12 December 2020

Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors

1 reference

12 December 2020

Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment

1 reference

12 December 2020

Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline

1 reference

12 December 2020

The utility of muscarinic agonists in the treatment of Alzheimer's disease

1 reference

12 December 2020

Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type.

1 reference

12 December 2020

Estrogens and estrogen-like non-feminizing compounds. Their role in the prevention and treatment of Alzheimer's disease.

1 reference

12 December 2020

Nicotinic treatment for cognitive dysfunction

1 reference

12 December 2020

Diminished production of proinflammatory cytokines in patients with Alzheimer's disease

1 reference

12 December 2020

Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

1 reference

12 December 2020

Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease.

1 reference

12 December 2020

A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life

1 reference

12 December 2020

Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application

1 reference

12 December 2020

Elimination of Amyloid beta Neurotoxicity

1 reference

12 December 2020

The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation

1 reference

12 December 2020

Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease

1 reference

12 December 2020

Effects of transdermal nicotine on learning, memory, verbal fluency, concentration, and general health in a healthy sample at risk for dementia

1 reference

12 December 2020

Rivastigmine exposure provided by a transdermal patch versus capsules.

1 reference

12 December 2020

Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment

1 reference

12 December 2020

Patients with Alzheimer's disease display a pro-inflammatory phenotype

1 reference

12 December 2020

AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease

1 reference

12 December 2020

Pharmacokinetic rationale for the rivastigmine patch

1 reference

12 December 2020

The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.

1 reference

12 December 2020

Estrogen receptor alpha and APOEepsilon4 polymorphisms interact to increase risk for sporadic AD in Italian females.

1 reference

12 December 2020

Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects

1 reference

12 December 2020

A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42)

1 reference

12 December 2020

Optimisation of treatment by applying programmable rate-controlled drug delivery technology

1 reference

12 December 2020

Mitochondrial dysfunction and Alzheimer's disease

1 reference

12 December 2020

Alzheimer disease and Down syndrome: factors in pathogenesis

1 reference

12 December 2020

Genetic aspects of Alzheimer's disease.

1 reference

12 December 2020

Association of estrogen receptor alpha gene with Alzheimer's disease: a case-control study.

1 reference

12 December 2020

Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain

1 reference

12 December 2020

Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms.

1 reference

12 December 2020

Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau.

1 reference

12 December 2020

Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.

1 reference

12 December 2020

Association of estrogen receptor alpha (ESR1) PvuII and XbaI polymorphisms with sporadic Alzheimer's disease and their effect on apolipoprotein E concentrations.

1 reference

12 December 2020

10.2165/00002512-200825090-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

19 August 2017

0 references

1 reference